Name:
COLCOT Trial and Benefits of Colchicine
Description:
COLCOT Trial and Benefits of Colchicine
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/124f6054-73de-4987-84ab-b968da18dc42/thumbnails/124f6054-73de-4987-84ab-b968da18dc42.jpeg?sv=2019-02-02&sr=c&sig=EzONWM2ysaXrZibP7BVI6%2BlyEukXW2R5n7vg9ZX6CHs%3D&st=2025-01-08T22%3A10%3A01Z&se=2025-01-09T02%3A15%3A01Z&sp=r
Duration:
T00H03M41S
Embed URL:
https://stream.cadmore.media/player/124f6054-73de-4987-84ab-b968da18dc42
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/124f6054-73de-4987-84ab-b968da18dc42/18770278.mp3?sv=2019-02-02&sr=c&sig=otbrRF4jlEAZV3rPTHBvKNi77vVPs4YujDJpBBZCnMM%3D&st=2025-01-08T22%3A10%3A01Z&se=2025-01-09T00%3A15%3A01Z&sp=r
Upload Date:
2022-02-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
>> Practice Impact Extra podcasts are derived from Hurst's The Heart Board Review, and other online resources available only through accesscardiology.com. [ Music ] >> Inflammation has become a major concern in atherosclerosis and particularly in cardiovascular disease. We've had the CANTOS Trial. We've had the methotrexate trial. But now the question is all -- since there's so many different pathways, what about colchicine?
[ Music ] Dr. Bernie here, and welcome to Practice Impact Extra. The COLCOT Trial, an exciting trial assessing the anti-inflammatory effects of colchicine in secondary prevention. There is ample evidence suggesting inflammation is a significant contributor to the initiation and progression of cardiovascular disease. Equally important is to realize that there are many pathways of inflammation outcomes with different anti-inflammatories may have completely different results.
We have the CANTOS Trial, and that trial was used to look at whether or not the anti-inflammatory agent canakinumab could decrease and prevent adverse cardiovascular events and lower HSCRP. And it did. However, another trial using methotrexate and another anti-inflammatory failed to show any of these similar benefits. Colchicine is an anti-inflammatory drug used for decades to treat gout, and recently, pericarditis.
The goal of the COLCOT Trial was to evaluate colchicine compared with placebo, administered for 30 days after a myocardial infarction. The trial enrolled 4,700 patients who were randomized to colchicine 0.5 milligrams a day versus placebo. And these patients were followed for 22 months. The primary endpoint was CV death, myocardial infarction, stroke, resuscitated cardiac arrest, urgent hospitalization of unstable angina leading to revascularization.
And what was noted is that the colchicine group had a 5.5% reduction compared to a 7.1% in the placebo group. That's a pretty impressive outcome. Where was the benefit primarily seen? Well, it was primarily seen due to reduction in the incidence of stroke and urgent hospitalization for acute coronary syndrome. There was a trend in the other components going in the right direction as well. So what's my take?
At first glance, this is an encouraging trial result. The question remains Should we use colchicine see more broadly, is still open. I believe this trial can become a landmark game changer if future clinical research trials are able to reduplicate and reconfirm the COLCOT colchicine Trial. So stay tuned. Thanks for joining me and see you next time on Practice Impact Extra.
>> We hope you enjoyed this podcast from McGraw-Hill. Subscribers to AccessCardiology have instant access to over 25,000 pages of rich medical content, receive medical updates from trusted experts, and have access to other special features. To subscribe or learn more, please visit accesscardiology.com.